UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000000843
Receipt number R000000989
Scientific Title A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)
Date of disclosure of the study information 2007/11/01
Last modified on 2021/08/27 13:43:48

No. Disposal Last modified on Item of update
1 Insert 2007/10/06 14:48:55
2 Update 2008/12/19 18:48:05 Homepage URL
Email
Email1
3 Update 2008/12/19 18:48:36 Key inclusion criteria
4 Update 2009/10/29 19:55:28 Recruitment status
5 Update 2009/11/16 15:36:35 UMIN ID1
6 Update 2009/11/18 11:47:56 Public title
Public title
7 Update 2012/05/16 14:16:22 Address
Name of person sending information
Division name
Address
Address
Post marketing survey by drug manufacture etc., specified by Japanese law.
Institutions
8 Update 2012/06/26 11:43:22 Recruitment status
9 Update 2013/06/17 16:12:11 Acronym
Acronym
10 Update 2014/05/12 14:11:35 Division name
TEL
Email
Last name of contact person
Last name of contact person
Division name
Division name
11 Update 2014/05/12 14:11:59 Publication of results
12 Update 2014/05/12 14:14:35 Key secondary outcomes
Key secondary outcomes
13 Update 2014/11/07 10:29:12 Address
Address
TEL
Address1
Tel1
Institutions
14 Update 2014/11/07 10:31:22 Last follow-up date
15 Update 2016/04/01 19:34:12 Name of primary person or sponsor
Organization
Institutions
16 Update 2016/06/13 09:29:19 Organization
Organization
17 Update 2016/06/15 15:32:17 Public title
Public title
18 Update 2016/06/15 15:37:40 Narrative objectives1
19 Update 2016/06/15 16:05:18 Key inclusion criteria
Key inclusion criteria
20 Update 2016/06/20 10:42:32 Key inclusion criteria
Key exclusion criteria
21 Update 2016/06/20 13:35:40 Key inclusion criteria
Key exclusion criteria
22 Update 2016/06/21 10:33:56 Institutions
23 Update 2016/07/20 11:35:09 Institute
Institute
24 Update 2017/01/11 14:45:57 Key inclusion criteria
Key inclusion criteria
25 Update 2017/01/11 15:04:57 Nationality of Funding Organization
Nationality of Funding Organization
26 Update 2017/01/20 17:16:50 Anticipated trial start date
27 Update 2017/01/20 17:23:08 Institutions
28 Update 2018/08/23 15:01:51 Recruitment status
Last follow-up date
Publication of results
29 Update 2019/11/21 16:26:29 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Organization
Division name
Zip code
Address
Address
Homepage URL
Organization1
Organization
Organization
Address
Address
Tel
Email
30 Update 2019/11/21 16:29:17 URL releasing protocol
URL related to results and publications
Number of participants that the trial has enrolled
31 Update 2019/11/21 16:49:30 Recruitment status
Date of IRB
Last follow-up date
32 Update 2021/08/13 16:40:07 URL releasing protocol
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
33 Update 2021/08/27 13:43:48
Last name of contact person

Last name of contact person